What's new

Orphan designation: Doxorubicin,Liposomal,Pegylated Treatment of soft-tissue sarcoma, 22/05/2025 Positive

Orphan designation: Doxorubicin,Liposomal,Pegylated Treatment of soft-tissue sarcoma, 22/05/2025 Positive

Jun 25, 2025 - 09:50
 0
Orphan designation: Doxorubicin,Liposomal,Pegylated Treatment of soft-tissue sarcoma, 22/05/2025 Positive
Orphan designation: Doxorubicin,Liposomal,Pegylated Treatment of soft-tissue sarcoma, 22/05/2025 Positive
Read More

Tags:

Previous Article

Orphan designation: Radiprodil Treatment of GRIN-related neurodevelopmental diso...

Next Article

Orphan designation: Tranilast Treatment of idiopathic pulmonary fibrosis, 22/05/...

Related Posts

Human medicines European public assessment report (EPAR): Zemcelpro, allogeneic umbilical cord-derived CD34- cells, non-expanded,dorocubicel, Status: Opinion

Human medicines European public assessment report (EPAR...

Jun 20, 2025  0

EMEA-000834-PIP01-10-M01

EMEA-000834-PIP01-10-M01

Jun 24, 2025  0

Summary of opinion: Nobivac L4, 12/06/2025 Positive

Summary of opinion: Nobivac L4, 12/06/2025 Positive

Jun 13, 2025  0